Removal of low-density lipoprotein from plasma by adsorption increases bradykinin and plasma nitric oxide levels in patients with peripheral atherosclerosis

Blood Coagulation and Fibrinolysis

Volumn 9, Issue 8, 1998, Pages 725-732

  Murashima, J ^b   Ueki, Yukitaka ^a   Matsunaga, Y ^b   Yano, M ^b   Matsumoto, K ^b   Miyake, S ^b   Tominaga, Y ^b   Eguchi, K ^b   Yano, K ^b  

^a SASEBO CHUO HOSPITAL   (Japan)

^b NONE

Author keywords

Bradykinin; Nitric oxide; Peripheral atherosclerosis

Indexed keywords

APOLIPOPROTEIN B; BRADYKININ; KININOGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; PREKALLIKREIN;

ADSORPTION; ADULT; AGED; ARTERY BLOOD FLOW; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KALLIKREIN KININ SYSTEM; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032448423     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199811000-00001     Document Type: Article

References (39)

1. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-374.
2. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-364.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-924.
4. Agishi T, Kitano Y, Suzuki T, Miura A, Murakami J, Minagawa H, et al. Improvement of peripheral circulation by low density lipoprotein adsorption. Asaio Trans 1989; 35: 349-351.
5. Naganuma S, Agishi T, Ota K. Effect of LDL apheresis on lipoprotein (A) levels in arteriosclerotic obliterans. Artif Organs 1991; 15: 336.
6. Agishi T, Naganuma S, Nakasato S, Kitajima K, Ota K, Ban K, Nomura M. Treatment of arteriosclerotic obstruction by LDL adsorption. Angiology 1993; 44: 222-227.
7. Sato Y, Agishi T. Low-density lipoprotein adsorption for arteriosclerotic patients. Artif Organs 1996; 20: 324-327.
8. Kojima S, Harada SM, Nomura S, Kimura G, Tsushima M, Kuramochi M, et al. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. Asaio Trans 1991; 37: 644-648.
9. Yamamoto A, Kojima S, Siba-Harada M, Kawaguchi A, Hatanaka K. Assessment of the biocompatibility and long-term effect of LDL-apheresis by dextran sulfate-cellulose column. Artif Organs 1992; 16: 177-181.
10. Mombouli JV, Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Anna Rev Pharmacol Toxicol 1995; 35: 679-705.
11. Yamamoto A, Yokoyama S, Satani M, Kikkawa T, Kishino B. Evaluation of selective LDL-removal in the treatment of familial hypercholesterolemia: double membrane filtration and adsorption system. Prog Clin Biol Res 1988; 255: 357-366.
12. Friedewald WT, Levy RI, Friedrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-504.
13. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996; 23: 230-236.
14. Dati F, Barthels M, Conard J. Multicenter evaluation of a chromogenic substrate method for photometric determination of prothrombin time. Thromb Haemost 1987; 58: 856-865.
15. Minami M, Togashi H, Sano M. Plasma bradykinin concentration in patients with essential hypertension, effort angina and other cardiac diseases. Folia Pharmacologica Japonica 1983; 82: 159-169.
16. Meier HL, Pierce JU, Colman RW, Kaplan AP. Activation and function of human Hageman factor. The role of high molecular weight kininogen and prekallikrein. J Clin Invest 1977; 60: 18-31.
17. Heimark RL, Kurachi K, Fujikawa K, Davie EW. Surface activation of blood coagulation, fibrinolysis, and kinin formation. Nature 1980; 286: 456-460.
18. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, LDL apheresis with dextran sulphate, and ACE inhibitors [letter]. Lancet 1992; 340: 908-909.
19. Kroon AA, Mol MJ, Stalenhoef AF. ACE inhibitors and LDL-apheresis with dextran sulphate adsorption [letter]. Lancet 1992; 340: 1476.
20. Keller C, Grutzmacher P, Bahr F, Schwarzbeck A, Kroon AA, Kiral A. LDL-apheresis with dextran sulphate and anaphylactoid reactions to ACE inhibitors [letter]. Lancet 1993; 341: 60-61.
21. Pound D. Kinin formation mechanisms and role of inflammatory disorders. Ann Rev Immunol 1988; 6: 49-83.
22. Koga N, Nagano T, Sato T, Kagasawa K. Anaphylactoid reactions and bradykinin generation in patients treated with LDL-apheresis and an ACE inhibitor. Asaio J 1993; 39: M288-M291.
23. Wiemer G, Scholkens BA, Becker RH, Busse R. Ramiprilat enhances endothelial autocoid formation by inhibiting breakdown of endothelium-derived bradykinin. Hypertension 1991; 18: 558-563.
24. Busse R, Fleming I, Hecker M. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy. J Cardiovasc Pharmacol 1993; 22: S31-S36.
25. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991; 41: 485-490.
26. Liew FY, Cox FE. Nonspecific defence mechanism: the role of nitric oxide. Immunol Today 1991; 12: A17-A21.
27. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
28. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxations of the arterial smooth muscle by acetylcholine. Nature 1980; 286: 373-376.
29. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 1984; 24: 175-197.
30. Minor RLJ, Myers PR, Guerra RJ, Bates JN, Harrison DG. Diet-induced atherosclerosis increases the release of nitrogen oxides from rabbit aorta. J Clin Invest 1990; 86: 2109-2116.
31. Mugge A, Lopez JA, Piegors DJ, Breese KR, Heistad DD. Acetylcholine-induced vasodilatation in rabbit hindlimb in vivo is not inhibited by analogues of L-arginine. Am J Physiol 1991; 260: H242-H247.
32. Wennmalm A, Benthin G, Edlund A, Jungersten L, Kieler JN, Lundin S, et al. Metabolism and excretion of nitric oxide in humans. An experimental and clinical study. Circ Res 1993; 73: 1121-1127.
33. Andrews HE, Bruckdorfer KR, Dunn RC, Jacobs M. Low-density lipoproteins inhibit endothelium-dependent relaxation in rabbit aorta. Nature 1987; 327: 237-239.
34. Chin JH, Azhar S, Hoffman BB. Inactivation of endothelial derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
35. Liao JK, Shin WW, Lee WY, Clark SL. Oxidized low-density lipoprotein decreased the expression of endothelial nitric oxide synthase. J Biol Chem 1995; 270: 319-324.
36. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
37. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-4655.
38. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-1058.
39. Uno H, Ueki Y, Murashima J, Miyake S, Tominaga Y, Eguchi K, et al. Removal of LDL from plasma by adsorption reduced adhesion molecules on mono-nuclear cells in patients with arterioscleritic obliterans. Atherosclerosis 1995; 116: 93-102.